(218 days)
No
The description focuses on the material composition and physical properties of the bone graft putty, with no mention of AI/ML capabilities or data processing.
Yes
The device is indicated for filling bone voids or defects of the skeletal system and is resorbed and replaced with bone during the healing process, indicating a therapeutic function.
No
The device is a bone graft putty intended for filling bone voids or defects in the skeletal system. Its purpose is to facilitate healing by being resorbed and replaced with bone, not to identify or diagnose conditions.
No
The device description clearly states it is a physical bone graft putty made of calcium phosphate granules and a polymer gel, intended for filling bone voids. It is a physical implant, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, or tissue) to provide information about a person's health.
- Osteo3 ZP Putty's Function: Osteo3 ZP Putty is a bone graft material intended for direct implantation into bone voids or defects within the skeletal system. It is a physical material that is resorbed and replaced by bone during the healing process.
- Lack of Specimen Analysis: The description and intended use clearly indicate that this device is implanted directly into the body and does not involve the analysis of specimens taken from the body.
Therefore, Osteo3 ZP Putty is a medical device, specifically a bone graft substitute, but it does not fit the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
Osteo3 ZP Putty is indicated for filling bone voids or defects of the skeletal system (i.e., the extremities, pelvis, and posterolateral spine) that are not intrinsic to the stability of the bony structure. These osseous defects may be surgically created or as a result of traumatic injury to the bone. Osteo 2 ZP Putty is a bone graft putty that is resorbed and replaced with bone during the healing process. Osteo3 ZP Putty must be used with morselized autograft bone at a ratio of 1:1 by volume in the posterolateral spine.
Product codes (comma separated list FDA assigned to the subject device)
MQV
Device Description
Osteo3 ZP Putty is an osteoconductive, resorbable, porous, 100% nanosynthetic calcium phosphate bone void filler. Osteo ZP Putty contains 5.8 wt% silicon-substituted calcium phosphate granules suspended in a resorbable polymer gel. The final, finished Osteo2 ZP Putty is 30 wt% granules and 70 wt% polymer gel. The high surface area porous granules have been designed to deliver consistent and rapid bone ingrowth, remodeling and cell-mediated resorption during the bone healing process. The aqueous polymer gel phase binds the highly porous granules into a moldable, pliable formulation which enables Osteo3 ZP Putty to be implanted directly from the packaging without any further gelation, mixing or graft setting time. Osteo3 ZP Putty is provided sterile to the end user in 5 cc and 10 cc sizes.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
extremities, pelvis, and posterolateral spine
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Non-clinical testing data were submitted according to the guidance documents Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Resorbable Calcium Salt Bone Void Filler Device (issued June 2003) and Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile (issued January 2016). The non-clinical testing data submitted, referenced, or relied upon to demonstrate substantial equivalence included chemical composition, physical properties, sterilization, material-mediated pyrogenicity, bacterial endotoxin, sterile barrier shelf life, product shelf life, and biocompatibility.
Animal testing was performed in a rabbit posterolateral spine fusion model to demonstrate substantial equivalence to the primary predicate device (K140375). Animals were evaluated after implantation with the subject device, the primary predicate device, and autograft (positive control). The study time points included baseline (time 0), 6 weeks, 9 weeks, and 12 weeks. Evaluation endpoints included manual palpation, range of motion/flexibility testing, plain and high-resolution radiography, micro-computed tomography (micro-CT) imaging, undecalcified histologic evaluation, and histomorphometric analysis. Decalcified paraffin histology sections also were graded according to ISO 10993-6 (Annex E).
A second animal study was performed in a rabbit critical-sized defect model to demonstrate substantial equivalence to the additional predicate device (K071206). Animals were evaluated after the defects were implanted with the subject device, the additional predicate device, or left unfilled (negative control). The study time points included baseline (time 0), 4 weeks, and 12 weeks. Evaluation endpoints included plain and high-resolution radiography, micro-computed tomography (micro-CT) imaging, undecalcified histologic evaluation, and histomorphometric analysis. Decalcified paraffin histology sections also were graded according to ISO 10993-6 (Annex E).
No clinical data were included in this submission.
The radiographic, histologic, and histomorphometric performance of the subject device were compared to that of the primary predicate device K140375 in a rabbit posterolateral fusion model. The results of the study, provided in Section 19 Performance Testing – Animal, demonstrated that the performance of the subject device was equivalent to that of the predicate device K140375 in the posterolateral spine.
Similarly, the radiographic, histologic, and histomorphometric performance of the subject device were compared to that of the additional predicate device K071206 in a rabbit critical-sized defect model. The results of the study, also provided in Section 19, demonstrated that the performance of the subject device was equivalent to that of the predicate device K071206 in the critical-sized defects.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 888.3045 Resorbable calcium salt bone void filler device.
(a)
Identification. A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
0
June 9, 2020
Image /page/0/Picture/1 description: The image contains the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left and features a stylized eagle. The FDA logo is on the right and features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
Sirakoss Ltd. % Kevin Thomas Vice President and Director of Regulatory Affairs PaxMed International, LLC 12264 El Camino Real, Suite 400 San Diego, California 92130
Re: K193075
Trade/Device Name: Osteo3 ZP Putty Regulation Number: 21 CFR 888.3045 Regulation Name: Resorbable Calcium Salt Bone Void Filler Device Regulatory Class: Class II Product Code: MQV Dated: May 8, 2020 Received: May 11, 2020
Dear Kevin Thomas:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for
1
devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Jesse Muir, Ph.D. Acting Assistant Director DHT6C: Division of Restorative, Repair, and Trauma Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name
Osteo3 ZP Putty
Indications for Use (Describe)
Osteo ZP Putty is indicated for filling bone voids or defects of the skeletal system (i.e., the extremities, pelvis, and posterolateral spine) that are not intrinsic to the stability of the bony structure. These osseous defects may be surgically created or as a result of traumatic injury to the bone. Osteo 2 ZP Putty is a bone graft putty that is resorbed and replaced with bone during the healing process. Osteo3 ZP Putty must be used with morselized autograft bone at a ratio of 1:1 by volume in the posterolateral spine.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ------------------------------------------------- | -- |
X | Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff @fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary K193075 Osteo³ ZP Putty SIRAKOSS Ltd. May 8, 2020
ADMINISTRATIVE INFORMATION
| Manufacturer Name | SIRAKOSS Ltd.
Level 4, Polwarth Building, Foresterhill
Aberdeen AB25 2ZD, United Kingdom
Telephone +44 1224 437846 |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Official Contact | Jordan Conway, PhD
R&D Manager |
| Representative/Consultant | Kevin A. Thomas, PhD
Floyd G. Larson, MS, MBA
PaxMed International, LLC
12264 El Camino Real, Suite 400
San Diego, CA 92130
Telephone: +1 858-792-1235
Fax: +1 858-792-1236 |
Email:
kthomas@paxmed.com flarson@paxmed.com
DEVICE NAME AND CLASSIFICATION
| Trade/Device Name | Osteo3 ZP Putty |
|---|---|
| Common Name | Filler, bone void, calcium compound |
| Regulation Number | 21 CFR 888.3045 |
| Regulation Name | Resorbable calcium salt bone void filler device |
| Regulatory Class | Class II |
| Product Code | MQV |
| Classification Panel | Orthopedic |
| Reviewing Office | |
| Reviewing Division | Office of Health Technology 6 (Orthopedic Devices) |
| Division of Health Technology 6 C | |
| (Restorative, Repair and Trauma Devices) |
PREDICATE DEVICE INFORMATION
Primary Predicate Device K140375, MASTERGRAFT® Strip; MASTERGRAFT® Putty, Medtronic Sofamor Danek USA, Inc. Additional Predicate Device K071206, Actifuse ™ ABX E-Z-fil Bone Graft Substitute, ApaTech Limited Reference Device K173525, NovoGro, OsteoNovus, Inc.
4
INDICATIONS FOR USE STATEMENT
Osteo3 ZP Putty is indicated for filling bone voids or defects of the skeletal system (i.e., the extremities, pelvis, and posterolateral spine) that are not intrinsic to the bony structure. These osseous defects may be surgically created or as a result of traumatic injury to the bone. Osteo3 ZP Putty is a bone graft putty that is resorbed and replaced with bone during the healing process. Osteo3 ZP Putty must be used with morselized autograft bone at a ratio of 1:1 by volume in the posterolateral spine.
SUBJECT DEVICE DESCRIPTION
Osteo3 ZP Putty is an osteoconductive, resorbable, porous, 100% nanosynthetic calcium phosphate bone void filler. Osteo ZP Putty contains 5.8 wt% silicon-substituted calcium phosphate granules suspended in a resorbable polymer gel. The final, finished Osteo2 ZP Putty is 30 wt% granules and 70 wt% polymer gel. The high surface area porous granules have been designed to deliver consistent and rapid bone ingrowth, remodeling and cell-mediated resorption during the bone healing process. The aqueous polymer gel phase binds the highly porous granules into a moldable, pliable formulation which enables Osteo3 ZP Putty to be implanted directly from the packaging without any further gelation, mixing or graft setting time. Osteo3 ZP Putty is provided sterile to the end user in 5 cc and 10 cc sizes.
PERFORMANCE DATA
Non-clinical testing data were submitted according to the guidance documents Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Resorbable Calcium Salt Bone Void Filler Device (issued June 2003) and Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile (issued January 2016). The non-clinical testing data submitted, referenced, or relied upon to demonstrate substantial equivalence included chemical composition, physical properties, sterilization, material-mediated pyrogenicity, bacterial endotoxin, sterile barrier shelf life, product shelf life, and biocompatibility.
Animal testing was performed in a rabbit posterolateral spine fusion model to demonstrate substantial equivalence to the primary predicate device (K140375). Animals were evaluated after implantation with the subject device, the primary predicate device, and autograft (positive control). The study time points included baseline (time 0), 6 weeks, 9 weeks, and 12 weeks. Evaluation endpoints included manual palpation, range of motion/flexibility testing, plain and high-resolution radiography, micro-computed tomography (micro-CT) imaging, undecalcified histologic evaluation, and histomorphometric analysis. Decalcified paraffin histology sections also were graded according to ISO 10993-6 (Annex E).
A second animal study was performed in a rabbit critical-sized defect model to demonstrate substantial equivalence to the additional predicate device (K071206). Animals were evaluated after the defects were implanted with the subject device, the additional predicate device, or left unfilled (negative control). The study time points included baseline (time 0), 4 weeks, and 12 weeks. Evaluation endpoints included plain and high-resolution radiography, micro-computed tomography (micro-CT) imaging, undecalcified histologic evaluation, and histomorphometric analysis. Decalcified paraffin histology sections also were graded according to ISO 10993-6 (Annex E).
No clinical data were included in this submission.
5
EQUIVALENCE TO MARKETED DEVICES
The subject device is substantially equivalent in indications and design principles to the primary predicate device, the additional predicate device, and the reference device listed above. Provided at the end of this summary are tables comparing the Indications for Use Statements and the technological characteristics of the subject device, the primary predicate device, the additional predicate device, and the reference device,
The primary predicate device is K140375 for substantial equivalence in the posterolateral spine animal model performance testing. The additional predicate device K071206 is for substantial equivalence in the critical-sized defect animal model performance testing. The reference device K173525 is in support of substantial equivalence in terms of the subject device material composition.
The subject device, the primary predicate device K140375, and the additional predicate device K071206, and the reference device K173525 have the same intended use, the same product classification and product code (MQV), and have similar Indications for Use statements. The subject device, the primary predicate device, the additional predicate device, and the reference device are indicated for use as standalone bone void fillers in the extremities and pelvis. The subject device, the primary predicate, and the reference device K173525 are indicated for use with autograft bone (as a bone graft extender) in the posterolateral spine; the additional predicate device K071206 is indicated for stand-alone use in the posterolateral spine. Although the subject device, the primary predicate device, the additional predicate device, and the reference device have slightly different Indications for Use language, these differences in language do not change the intended use as a bone void filler.
The subject device, the primary predicate device, the additional predicate device, and the reference device all incorporate calcium phosphate materials within a polymeric binder or scaffold. The subject device polymeric binder is a resorbable polymer that is similar to that of the additional predicate device K071206. The subject device, the additional predicate device K071206, and the reference device K173525 each include silicon in the mineral component; the amount of silicon in the subject device is within the range of the amount of silicon in K071206 and K173525.
The subject device, the additional predicate device K071206, and the reference device K173525 also are similar in physical form (putty), and are provided in similar packaging to the end user (delivery syringe). The subject device, the primary predicate device, the additional predicate device, and the reference device are provided sterile for single-patient, single-use in similar ranges of graft volumes.
The radiographic, histologic, and histomorphometric performance of the subject device were compared to that of the primary predicate device K140375 in a rabbit posterolateral fusion model. The results of the study, provided in Section 19 Performance Testing – Animal, demonstrated that the performance of the subject device was equivalent to that of the predicate device K140375 in the posterolateral spine.
Similarly, the radiographic, histologic, and histomorphometric performance of the subject device were compared to that of the additional predicate device K071206 in a rabbit critical-sized defect model. The results of the study, also provided in Section 19, demonstrated that the performance of the subject device was equivalent to that of the predicate device K071206 in the critical-sized defects.
6
CONCLUSION
The subject device, the primary predicate device, the additional predicate device, and the reference device have the same intended use, have similar technological characteristics, and are made of similar materials. The subject device, the primary predicate, the additional predicate device, and reference device encompass the same range of physical dimensions, are packaged in similar materials and are sterilized using similar methods. The data included in this submission demonstrate substantial equivalence to the predicate device, the additional predicate device, and the reference device listed above.
7
Table of Substantial Equivalence
| Comparison | Subject Device | Primary Predicate Device | Additional Predicate Device | Reference Device |
|---|---|---|---|---|
| Osteo3 ZP Putty | ||||
| SIRAKOSS Ltd. | K140375 | |||
| MASTERGRAFT® Strip; MASTERGRAFT® Putty | ||||
| Medtronic Sofamor Danek USA, Inc. | K071206 | |||
| Actifuse ™ ABX E-Z-fil Bone Graft Substitute | ||||
| ApaTech Limited | K173525 | |||
| NovoGro | ||||
| OsteoNovus, Inc. | ||||
| Indications for Use Statement | Osteo3 ZP Putty is indicated for filling bone voids or defects of | |||
| the skeletal system (i.e., the extremities, pelvis, and | ||||
| posterolateral spine) that are not intrinsic to the stability of the | ||||
| bony structure. These osseous defects may be surgically created | ||||
| or as a result of traumatic injury to the bone. Osteo3 ZP Putty is a | ||||
| bone graft putty that is resorbed and replaced with bone during | ||||
| the healing process. Osteo3 ZP Putty must be used with | ||||
| morselized autograft bone at a ratio of 1:1 by volume in the | ||||
| posterolateral spine. | MASTERGRAFT® Putty combined with either autogenous bone | |||
| marrow, and/or sterile water, and/or autograft is indicated as a | ||||
| bone void filler for bony voids or gaps that are not intrinsic to | ||||
| the stability of the bony structure. Additionally, | ||||
| MASTERGRAFT® Putty can be used with autograft as a bone | ||||
| graft extender. MASTERGRAFT® Putty is to be gently packed | ||||
| into bony voids or gaps of the skeletal system (e.g., the | ||||
| posterolateral spine, pelvis, ilium, and/or extremities). These | ||||
| defects may be surgically created osseous defects or osseous | ||||
| defects created from traumatic injury to the bone. | ||||
| MASTERGRAFT® Putty resorbs and is replaced with bone | ||||
| during the healing process. | Actifuse is a bone void filler intended only for orthopaedic | |||
| applications as a filler for gaps and voids that are not intrinsic to | ||||
| the stability of the bony structure. Actifuse is indicated to be | ||||
| packed gently into bony voids or gaps of the skeletal system, i.e., | ||||
| extremities, pelvis, and spine, including use in posterolateral | ||||
| fusion procedures with appropriate stabilizing hardware. These | ||||
| defects may be surgically created osseous defects or osseous | ||||
| defects created from traumatic injury to the bone. The product | ||||
| provides a bone void filler that resorbs and is replaced by bone | ||||
| during the healing process. | NovoGro Putty is an implant intended to fill bony voids or gaps | |||
| of the skeletal system (i.e. extremities, posterolateral spine and | ||||
| pelvis). NovoGro must be used with autograft as a bone | ||||
| extender in the posterolateral spine. These osseous defects may | ||||
| be surgically created or the result of traumatic injury to the bone | ||||
| and are not intrinsic to the stability of the bony structure. The | ||||
| device resorbs and is replaced with bone during the healing | ||||
| process. | ||||
| Product Code | MQV | MQV | MQV | MQV |
| Intended Use | Bone void filler for skeletal system | |||
| (extremities, pelvis, and posterolateral spine) | Bone void filler for skeletal system | |||
| (extremities, pelvis, and posterolateral spine) | Bone void filler for skeletal system | |||
| (extremities, pelvis, and posterolateral spine) | Bone void filler for skeletal system | |||
| (extremities, pelvis, and posterolateral spine) | ||||
| Reason for Predicate | Not applicable | Performance in animal model in the posterolateral spine | ||
| (as extender with autograft) | Performance in animal model in critical-sized defects | |||
| (as stand-alone bone void filler) | Reference device for silicon mineral component | |||
| Design | ||||
| Form | Irregularly shaped granules premixed with a soluble aqueous gel | |||
| carrier | Granules uniformly dispersed in collagen scaffold | Irregularly shaped granules premixed with a soluble aqueous gel | ||
| carrier | Regularly shaped granules premixed with a soluble polymeric | |||
| binder | ||||
| Granule Size | 1-2 mm (1000 – 2000 μm) | 0.5 mm - 1.6 mm in diameter | 1 - 2 mm (1000 – 2000 μm) | 1 - 2 mm (1000 – 2000 μm) |
| Porosity | Granules > 75 % | Granules – 80 % | ||
| Final device - not stated in 510(k) Summary | Granules 80 % | 31.3% | ||
| Materials | ||||
| Mineral component | ||||
| Calcium salts | Silicated calcium phosphate | β-tricalcium phosphate (85 %) and Hydroxyapatite (15 %) | Silicated calcium phosphate | monetite / newberyite / sodium hydrogen phosphate |
| $[CaHPO4 + Mg(PO3OH)•3(H2O) + NaH2PO4]$ | ||||
| Silicon | 5.8 % by weight | Not applicable | 0.8 % by weight | 14% by weight |
| Scaffold/Binder | Aqueous gel carrier (resorbable polymer) | Type I bovine collagen | Aqueous gel carrier (resorbable polymer, not specified) | Sodium carboxymethyl cellulose (CMC) |
| Hydrate prior to use | No | Bone marrow aspirate and/or sterile water (required) | No | Yes (supplied as dry powder and aqueous solution, |
| mixed prior to use) | ||||
| For Use in Extremities and Pelvis | Yes | Yes | Yes | Yes |
| Mix with bone prior to use | No | Autograft bone (optional) | No | No |
| For Use in Posterolateral Spine | Yes | Yes | Yes | Yes |
| Mix with bone prior to use | Mix with autograft bone required for posterolateral spine | Autograft bone (required) | No | Mix with autograft bone required for posterolateral spine |
| How Provided | ||||
| Sizes | Provided in delivery syringe | |||
| Volumes: 5 cc, 10 cc | MASTERGRAFT® Putty | |||
| Various volumes: | ||||
| 0.75 cc, 1.5 cc, 3.0 cc, 6.0 cc, and 9.0 cc packages | Provided in delivery syringe | |||
| Volumes ranging from 1.5 mL to 20 mL | Provided in mixing/delivery syringe | |||
| Final graft volumes ranging from 1 cc – 20 cc | ||||
| Sterility | Provided sterile to end-user | Provided sterile to end-user | Provided sterile to end-user | Provided sterile to end-user |
| Sterilization | Gamma irradiation | Irradiation | E-beam irradiation | Gamma irradiation |
| Usage | Single-patient, single-use | Single-patient, single-use | Single-patient, single-use | Single-patient, single-use |